SCORE Search Results Details for Application 10516759 and Search Result 20091123_110100_us-10-516-759a-14_copy_24_81.rag.

Score Home Page | Retrieve Application List | SCORE System Overview | SCORE FAQ | Comments / Suggestions

This page gives you Search Results detail for the Application 10516759 and Search Result 20091123_110100_us-10-516-759a-14_copy_24_81.rag.

Go Back to previous page

OM protein - protein search, using sw model

Run on: November 23, 2009, 11:13:51 ; Search time 57 Seconds
(without alignments)
960.024 Million cell updates/sec

Title: US-10-516-759A-14_COPY_24_81
Perfect score: 350
Sequence: 1 DIKHNRPRRDCVAEGKVCDP.....RNYSRGGVCVTHCNFLNGEP 58

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 5029790 seqs, 943472257 residues

Total number of hits satisfying chosen parameters: 5029790

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_200907:*
1: geneseqp1:*
2: geneseqp2:*
3: geneseqp3:*

SUMMARIES

%

Result No.	Score	Query Match	Length	DB	ID	Description

1	350	100.0	82	1	ADE36725	Ade36725 Human Erb
2	350	100.0	89	1	ADE36731	Ade36731 Human Erb
3	350	100.0	531	2	AJE77228	Aje77228 Human Erb
4	350	100.0	569	2	AOJ20844	Aoj20844 Human Erb
5	350	100.0	569	3	AUP69764	Aup69764 Human Erb
6	350	100.0	570	2	AEH24404	Aeh24404 HUMEGFRBB
7	350	100.0	621	2	AOG42613	Aog42613 Human HER
8	350	100.0	621	2	AOG42228	Aog42228 Human HER
9	350	100.0	624	2	AEH24397	Aeh24397 HUMEGFRBB
10	350	100.0	624	2	AEH24406	Aeh24406 HUMEGFRBB
11	350	100.0	625	2	ATT39332	Att39332 Human ERB
12	350	100.0	626	2	ATT39333	Att39333 Human ERB
13	350	100.0	640	1	ADE36713	Ade36713 Human Erb
14	350	100.0	640	1	ADW39268	Adw39268 Human Erb
15	350	100.0	699	2	AEH24399	Aeh24399 HUMEGFRBB
16	350	100.0	824	2	ATT39331	Att39331 Human ERB
17	350	100.0	843	2	ATT39330	Att39330 Human ERB
18	350	100.0	857	2	AOG42248	Aog42248 Human HER
19	350	100.0	866	2	AOG42602	Aog42602 Human HER
20	350	100.0	1298	2	AEK41239	Aek41239 Human tyr
21	350	100.0	1300	2	AOJ20843	Aoj20843 Human Erb
22	350	100.0	1302	2	AOJ20845	Aoj20845 Human Erb
23	350	100.0	1342	1	AAR13833	Aar13833 HER-3 epi
24	350	100.0	1342	1	AAR88453	Aar88453 erbB-3 po
25	350	100.0	1342	1	AAW69406	Aaw69406 ErbB-3 gl
26	350	100.0	1342	1	AAY16594	Aay16594 erbB-3 pr
27	350	100.0	1342	1	AAG65359	Aag65359 Human Her
28	350	100.0	1342	1	ADE62708	Ade62708 Human Pro
29	350	100.0	1342	1	ADB67646	Adb67646 Human epi
30	350	100.0	1342	1	ADB67617	Adb67617 Human epi
31	350	100.0	1342	1	ADB67645	Adb67645 Human epi
32	350	100.0	1342	1	ADB67647	Adb67647 Human epi
33	350	100.0	1342	1	ADB67642	Adb67642 Human epi
34	350	100.0	1342	1	ADB67644	Adb67644 Human epi
35	350	100.0	1342	1	ADB67643	Adb67643 Human epi
36	350	100.0	1342	1	ADN39920	Adn39920 Cancer/an
37	350	100.0	1342	1	ADA37256	Ada37256 Human Erb
38	350	100.0	1342	1	ADM10301	Adm10301 Human epi
39	350	100.0	1342	1	ADD52685	Add52685 Human erb
40	350	100.0	1342	1	ADE36712	Ade36712 Human Erb
41	350	100.0	1342	1	ADW39267	Adw39267 Human Erb
42	350	100.0	1342	1	ADJ66656	Adj66656 Her3 prot
43	350	100.0	1342	1	ADO56208	Ado56208 Human Erb
44	350	100.0	1342	1	ADP54346	Adp54346 Human PRO
45	350	100.0	1342	1	ADQ19366	Adq19366 Human sof

ALIGNMENTS

RESULT 1
ADE36725
ID   ADE36725 standard; protein; 82 AA.
XX
AC   ADE36725;
XX
DT   29-JAN-2004 (first entry)
XX
DE   Human ErbB-3-f12 amino acid sequence SEQ ID NO:14.
XX
KW   neoplasm; ErbB-3; immune response; cytostatic; gene therapy; cancer;
KW   human.
XX
OS   Homo sapiens.
XX
PN   WO2003080835-A1.
XX
PD   02-OCT-2003.
XX
PF   26-MAR-2003; 2003WO-CN000217.
XX
PR   26-MAR-2002; 2002CN-00116259.
XX
PA   (ZENS-) ZENSUN SHANGHAI SCI TECH LTD.
XX
PI   Zhou M;
XX
DR   WPI; 2003-876924/81.
XX
PT   Use of an ErbB-3 protein, a nucleic acid encoding an ErbB-3 protein or
PT   their fragments, for treating, preventing or delaying neoplasms (e.g.
PT   urethra, uterus, vagina or vulva neoplasm) or cancers (e.g. breast, ovary
PT   or colon cancer).
XX
PS   Claim 22; SEQ ID NO 14; 68pp; English.
XX
CC   The present invention describes a method for treating, preventing or
CC   delaying neoplasm in a mammal. The method comprises administering an ErbB
CC   -3 protein, a nucleic acid encoding an ErbB-3 protein, or their
CC   functional fragments, where an immune response is generated against the
CC   neoplasm. ErbB-3 has cytostatic activity, and can be used in gene
CC   therapy. The method is useful for treating, preventing or delaying
CC   neoplasms (e.g. adrenal gland, anus, auditory nerve, bile ducts, bladder,
CC   bone, brain, breast, buccal, central nervous system, cervix, colon, ear,
CC   endometrium, oesophagus, eye, eyelids, fallopian tube, gastrointestinal
CC   tract, head and neck, heart, kidney, larynx, liver, lung, mandible,
CC   mandibular condyle, maxilla, mouth, nasopharynx, nose, oral cavity,

```
CC   ovary, pancreas, parotid gland, penis, pinna, pituitary, prostate gland,
CC   rectum, retina, salivary glands, skin, small intestine, spinal cord,
CC   stomach, testes, thyroid, tonsil, urethra, uterus, vagina,
CC   vestibulocochlear nerve, or vulva neoplasm), or cancers (breast, ovary,
CC   stomach, prostate, colon and lung cancer). The present sequence
CC   represents a human ErbB-3 amino acid sequence, which is used in the
CC   exemplification of the present invention. N.B. The present sequence is
CC   designated as SEQ ID NO:14 in the Sequence Listing but does not
CC   correspond with the SEQ ID NO:14 given in figure 23.
XX
SQ   Sequence 82 AA;

  Query Match             100.0%;  Score 350;  DB 1;  Length 82;
  Best Local Similarity   100.0%;
  Matches   58;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 DIKHNRPRRDCVAEGKVCDPLCSSGGCWGPGPGQCLSCRNYSRGGVCVTHCNFLNGEP 58
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         24 DIKHNRPRRDCVAEGKVCDPLCSSGGCWGPGPGQCLSCRNYSRGGVCVTHCNFLNGEP 81


RESULT 2
ADE36731
ID   ADE36731 standard; protein; 89 AA.
XX
AC   ADE36731;
XX
DT   29-JAN-2004  (first entry)
XX
DE   Human ErbB-3-f12 amino acid sequence SEQ ID NO:14.
XX
KW   neoplasm; ErbB-3; immune response; cytostatic; gene therapy; cancer;
KW   human.
XX
OS   Homo sapiens.
XX
PN   WO2003080835-A1.
XX
PD   02-OCT-2003.
XX
PF   26-MAR-2003; 2003WO-CN000217.
XX
PR   26-MAR-2002; 2002CN-00116259.
XX
PA   (ZENS-) ZENSUN SHANGHAI SCI TECH LTD.
XX
PI   Zhou M;
XX
DR   WPI; 2003-876924/81.
```

DR   N-PSDB; ADE36730.
XX
PT   Use of an ErbB-3 protein, a nucleic acid encoding an ErbB-3 protein or
PT   their fragments, for treating, preventing or delaying neoplasms (e.g.
PT   urethra, uterus, vagina or vulva neoplasm) or cancers (e.g. breast, ovary
PT   or colon cancer).
XX
PS   Claim 22; Fig 23; 68pp; English.
XX
CC   The present invention describes a method for treating, preventing or
CC   delaying neoplasm in a mammal. The method comprises administering an ErbB
CC   -3 protein, a nucleic acid encoding an ErbB-3 protein, or their
CC   functional fragments, where an immune response is generated against the
CC   neoplasm. ErbB-3 has cytostatic activity, and can be used in gene
CC   therapy. The method is useful for treating, preventing or delaying
CC   neoplasms (e.g. adrenal gland, anus, auditory nerve, bile ducts, bladder,
CC   bone, brain, breast, buccal, central nervous system, cervix, colon, ear,
CC   endometrium, oesophagus, eye, eyelids, fallopian tube, gastrointestinal
CC   tract, head and neck, heart, kidney, larynx, liver, lung, mandible,
CC   mandibular condyle, maxilla, mouth, nasopharynx, nose, oral cavity,
CC   ovary, pancreas, parotid gland, penis, pinna, pituitary, prostate gland,
CC   rectum, retina, salivary glands, skin, small intestine, spinal cord,
CC   stomach, testes, thyroid, tonsil, urethra, uterus, vagina,
CC   vestibulocochlear nerve, or vulva neoplasm), or cancers (breast, ovary,
CC   stomach, prostate, colon and lung cancer). The present sequence
CC   represents a human ErbB-3 amino acid sequence, which is used in the
CC   exemplification of the present invention. N.B. The present sequence is
CC   designated as SEQ ID NO:14 in figure 23 but does not correspond with the
CC   SEQ ID NO:14 given in the Sequence Listing.
XX
SQ   Sequence 89 AA;

  Query Match   100.0%; Score 350; DB 1; Length 89;
  Best Local Similarity   100.0%;
  Matches   58; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 DIKHNRPRRDCVAEGKVCDPLCSSGGCWGPGPGQCLSCRNYSRGGVCVTHCNFLNGEP 58
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   24 DIKHNRPRRDCVAEGKVCDPLCSSGGCWGPGPGQCLSCRNYSRGGVCVTHCNFLNGEP 81

RESULT 3
AJE77228
ID   AJE77228 standard; protein; 531 AA.
XX
AC   AJE77228;
XX
DT   18-OCT-2007 (first entry)
XX

DE Human ErbB3 tyrosine kinase receptor ectodomain protein (aa: 1-531).
XX
KW Diagnosis; prognosis; therapeutic; cancer;
KW Erbb3 tyrosine kinase receptor.
XX
OS Homo sapiens.
XX
PN WO2007092932-A2.
XX
PD 16-AUG-2007.
XX
PF 08-FEB-2007; 2007WO-US061863.
XX
PR 08-FEB-2006; 2006US-0771237P.
PR 05-OCT-2006; 2006US-0828343P.
XX
PA (TARG-) TARGETED MOLECULAR DIAGNOSTICS LLC.
PA (YEDA) YEDA RES & DEV CO LTD.
XX
PI Bacus SS, Hill JE, Yarden Y, Kochupurakkal BS;
XX
DR WPI; 2007-690352/64.
DR N-PSDB; AJE77227.
DR REFSEQ; NP_001973.
XX
PT New bivalent binding molecule having binding affinity for ErbB ligand at
PT separate binding sites in a single covalently joined protein molecule,
PT useful for treating a disease or condition by removal or inhibition of an
PT ErbB ligand.
XX
PS Claim 10; SEQ ID NO 6; 37pp; English.
XX
CC The present invention relates to new bivalent ErbB-based ligand binding
CC molecules along with their method of preparation and use. The binding
CC molecule can be a protein expressed from a recombinant DNA molecule and
CC contain two extracellular domains of an ErbB receptor wherein both the
CC domains bind to ErbB receptor ligands. These binding molecules act as
CC traps to bind and sequester ligands, thus making them unavailable for
CC binding to cellular ErbB receptors. The bivalent binding molecules and
CC methods of the invention are useful for diagnosing and prognosing cancer
CC and treating a disease or condition that is improved, ameliorated or
CC inhibited by removal or inhibition of an ErbB ligand. The present
CC sequence is human erythroblastic leukemia viral oncogene homolog 3
CC tyrosine kinase receptor (ErbB3 tyrosine kinase receptor; HER3) receptor
CC ectodomain protein. Note: The sequence data for this patent did not form
CC part of the printed specification, but was obtained in electronic format
CC directly from WIPO at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 531 AA;

```
  Query Match             100.0%;  Score 350;  DB 2;  Length 531;
  Best Local Similarity   100.0%;
  Matches   58;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 DIKHNRPRRDCVAEGKVCDPLCSSGGCWGPGPGQCLSCRNYSRGGVCVTHCNFLNGEP 58
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        464 DIKHNRPRRDCVAEGKVCDPLCSSGGCWGPGPGQCLSCRNYSRGGVCVTHCNFLNGEP 521


RESULT 4
AOJ20844
ID   AOJ20844 standard; protein; 569 AA.
XX
AC   AOJ20844;
XX
DT   06-MAR-2008  (first entry)
XX
DE   Human ErbB3 receptor tyrosine kinase protein SEQ:97.
XX
KW   splicing; gene identification signature analysis; therapeutic; diagnosis;
KW   cancer; cytostatic; inflammation; antiinflammatory; autoimmune disease;
KW   immunosuppresive; graft rejection.
XX
OS   Homo sapiens.
XX
PN   WO2005071059-A2.
XX
PD   04-AUG-2005.
XX
PF   27-JAN-2005; 2005WO-IL000107.
XX
PR   27-JAN-2004; 2004US-0539128P.
PR   15-JUN-2004; 2004US-0579202P.
XX
PA   (COMP-) COMPUGEN LTD.
XX
PI   Sorek R,  Pollock S,  Diber A,  Levine Z,  Nemzer S,  Kol G,  Wool A;
PI   Haviv A,  Cohen Y,  Cohen Y,  Shemesh R,  Savitsky K;
XX
DR   WPI; 2005-555488/56.
XX
PT   Identifying alternatively spliced exons, involves scoring each of several
PT   exon sequences derived from genes of species according to one or more
PT   sequence parameters.
XX
PS   Example 3; SEQ ID NO 97; 991pp; English.
XX
CC   The present invention relates to a novel method of identifying (M1)
```

CC alternatively spliced exons. The method comprises scoring each of several
CC exon sequences derived from genes of a species according to at least one
CC sequence parameter, where the exon sequences of the several exon
CC sequences scoring above a predetermined threshold represent alternatively
CC spliced exons, thus identifying the alternatively spliced exons. Also
CC claimed are: a system (S1) for generating a database of alternatively
CC spliced exons; predicting (M2) expression products of a gene of interest
CC and analyzing chromosomal location of each of the alternatively spliced
CC exons with respect to coding sequence of the gene of interest to thus
CC predict expression products of the gene of interest. (M1) is useful for
CC identifying alternatively spliced exons. (S1) is useful for generating a
CC database of alternatively spliced exons. The DNA and the protein
CC sequences of the invention are useful for the diagnosis and/or treatment
CC of the diseases like cancer, inflammatory disease, autoimmune disease,
CC allergy and graft rejection. The present sequence represents a human
CC ErbB3 receptor tyrosine kinase protein.
XX
SQ Sequence 569 AA;

Query Match 100.0%; Score 350; DB 2; Length 569;
Best Local Similarity 100.0%;
Matches 58; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 DIKHNRPRRDCVAEGKVCDPLCSSGGCWGPGPGQCLSCRNYSRGGVCVTHCNFLNGEP 58
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        483 DIKHNRPRRDCVAEGKVCDPLCSSGGCWGPGPGQCLSCRNYSRGGVCVTHCNFLNGEP 540
```

RESULT 5
AUP69764
ID AUP69764 standard; protein; 569 AA.
XX
AC AUP69764;
XX
DT 19-FEB-2009 (first entry)
XX
DE Human Erbb3 tyrosine kinase receptor (delta15HER3) protein SEQ ID NO: 12.
XX
KW tumor marker; protein therapy; therapeutic; ovary tumor; cytostatic;
KW endocrine-gen.; gynecological; uropathic; breast tumor;
KW hyperproliferation; cancer; lung tumor; respiratory-gen.; stomach tumor;
KW gastrointestinal-gen.; colon tumor; pulmonary fibrosis; antiinflammatory;
KW Erbb3 tyrosine kinase receptor; HER3;
KW human epidermal growth factor receptor 3.
XX
OS Homo sapiens.
XX
PN WO2008153933-A2.
XX

PD 18-DEC-2008.
XX
PF 06-JUN-2008; 2008WO-US007111.
XX
PR 06-JUN-2007; 2007US-0942319P.
PR 20-AUG-2007; 2007US-0956887P.
XX
PA (AVIB-) AVI BIOPHARMA INC.
XX
PI Kole R, Sazani P, Wan J;
XX
DR WPI; 2009-A43572/02.
DR N-PSDB; AUP69763.
XX
PT New soluble, human epidermal growth factor receptor-2 (HER2) splice
PT variant protein is HER2 antagonist, useful for the treatment of
PT proliferative diseases e.g. ovarian or breast cancer and pulmonary
PT fibrosis.
XX
PS Disclosure; SEQ ID NO 12; 86pp; English.
XX
CC The present invention relates to novel isolated soluble human epidermal
CC growth factor receptor 2 and 3 (HER2 and HER3) proteins with HER2 and
CC HER3 antagonist activity and anti-proliferative properties. The invention
CC further discloses (i) an isolated nucleic acid encoding HER2 but lacking
CC exon 15 of the normal HER2 transcript, with exon 14 joined directly to
CC exon 16, and containing a stop codon within exon 16, (ii) a splice-
CC switching compound comprising an oligonucleotide between 12-30 bases and
CC at least 12 contiguous bases complementary to an exon-15 or 14 acceptor
CC or donor splice site region contained within SEQ ID NO: 15 and (iii) a
CC method of treating a subject having ovarian or breast cancer
CC characterized by over expression of human epidermal growth factor
CC receptor-2 (HER2), which involves administering HER2 or the compound
CC comprising an oligonucleotide to the subject. The isolated soluble human
CC epidermal growth factor receptor-2 (HER2) protein of the invention is
CC useful treating a subject having ovarian or breast cancer characterized
CC by over expression of human epidermal growth factor receptor-2 (HER2),
CC and proliferative diseases such as cancer (lung, gastric and colon
CC cancer) and pulmonary fibrosis. The present sequence represents a human
CC Erbb3 tyrosine kinase receptor (delta15HER3) protein.
XX
SQ Sequence 569 AA;

Query Match 100.0%; Score 350; DB 3; Length 569;
Best Local Similarity 100.0%;
Matches 58; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 DIKHNRPRRDCVAEGKVCDPLCSSGGCWGPGPGQCLSCRNYSRGGVCVTHCNFLNGEP 58
||||||||||||||||||||||||||||||||||||||||||||||||||||

```
Db        483 DIKHNRPRRDCVAEGKVCDPLCSSGGCWGPGPGQCLSCRNYSRGGVCVTHCNFLNGEP 540


RESULT 6
AEH24404
ID   AEH24404 standard; protein; 570 AA.
XX
AC   AEH24404;
XX
DT   29-JUN-2006  (first entry)
XX
DE   HUMEGFRBB3_PEA_1_P53 polypeptide.
XX
KW   diagnostic; prognosis; genetic marker; screening; cancer; cytostatic;
KW   neoplasm; HUMEGFRBB3_PEA_1_P53; protein-tyrosine kinase erbB-3 precursor;
KW   ERBB3.
XX
OS   Homo sapiens.
XX
PN   WO2006043271-A1.
XX
PD   27-APR-2006.
XX
PF   16-OCT-2005; 2005WO-IL001096.
XX
PR   22-OCT-2004; 2004US-0621004P.
PR   18-NOV-2004; 2004US-0628529P.
XX
PA   (COMP-) COMPUGEN LTD.
XX
PI   Novik A,  Pollock S,  Levine Z,  Dahary D,  Sorek R,  Sella-Tavor O;
PI   Cohen-Dayag A,  Sameach-Greenwald S,  Walach S;
XX
DR   WPI; 2006-331789/34.
DR   N-PSDB; AEH24321.
XX
PT   New isolated polynucleotide and polypeptide markers, useful as diagnostic
PT   markers for diagnosing diseases, predicting response to treatment,
PT   monitoring treatment, or determining prognosis of a marker-detectable
PT   disease.
XX
PS   Example 5; SEQ ID NO 144; 421pp; English.
XX
CC   The invention describes an isolated polynucleotide comprising
CC   HUMA1ACM_PEA 2 _T21, HUMA1ACM_PEA 2 _T27, or HUMA1ACM_PEA 2 _T7
CC   comprising 1320, 1239, or 2713 bp (SEQ ID NO. 1, 2, or 3). Also described
CC   are: an isolated polypeptide selected from HUMA1ACM_PEA 2 _P36 (SEQ ID
CC   NO. 51), HUMA1ACM_PEA 2 _P49 (SEQ ID NO. 52), or HUMA1ACM_PEA 2 _P59 (SEQ
CC   ID NO. 53); an isolated polypeptide encoding for a head of: (a)
```

CC HUMA1ACM_PEA 2 _P36 comprising a polypeptide 70% homologous to SEQ ID NO.
CC 180 or 182 of HUMA1ACM_PEA 2 _P36; (b) HUMA1ACM_PEA 2 _P49 comprising a
CC polypeptide 70% homologous to SEQ ID NO. 182 of HUMA1ACM_PEA 2 _P49; or
CC (c) HUMA1ACM_PEA 2 _P59 comprising a polypeptide 70% homologous to SEQ ID
CC NO. 182 of HUMA1ACM_PEA 2 _P59; an isolated polypeptide encoding for a
CC tail of: (a) HUMA1ACM_PEA 2 _P36 comprising a polypeptide 70% homologous
CC to SEQ ID NO. 181 in HUMA1ACM_PEA 2 _P36; (b) HUMA1ACM_PEA 2 _P49
CC comprising a polypeptide 70% homologous to SEQ ID NO. 183 in HUMA1ACM_PEA
CC 2 _P49; or (c) HUMA1ACM_PEA 2 _P59 comprising a polypeptide 70%
CC homologous to SEQ ID NO. 185 or 208 in HUMA1ACM_PEA 2 _P59; a primer pair
CC comprising a pair of isolated oligonucleotides capable of amplifying the
CC amplicon; an antibody capable of specifically binding to an epitope of
CC the amino acid sequence; a kit for detecting a marker-detectable disease
CC comprising a kit detecting specific expression of a splice variant; a
CC biomarker capable of detecting marker-detectable disease comprising the
CC nucleic acid sequences or amino acid sequence, or its fragments. The
CC polynucleotides and polypeptides are useful as diagnostic markers for
CC diagnosing and screening for diseases diseases e.g., cancer, selecting a
CC therapy for a marker-detectable disease and determining prognosis of a
CC marker-detectable disease, as well as for predicting response to
CC treatment and monitoring treatment. This sequence represents a
CC HUMEGFRBB3_PEA_1_P53 polypeptide, a transcript from the HUMEGFRBB3
CC cluster and variant of protein-tyrosine kinase erbB-3 precursor useful as
CC a diagnostic marker.
XX
SQ Sequence 570 AA;

Query Match 100.0%; Score 350; DB 2; Length 570;
Best Local Similarity 100.0%;
Matches 58; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 DIKHNRPRRDCVAEGKVCDPLCSSGGCWGPGPGQCLSCRNYSRGGVCVTHCNFLNGEP 58
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        483 DIKHNRPRRDCVAEGKVCDPLCSSGGCWGPGPGQCLSCRNYSRGGVCVTHCNFLNGEP 540
```

RESULT 7
AOG42613
ID AOG42613 standard; protein; 621 AA.
XX
AC AOG42613;
XX
DT 06-MAR-2008 (first entry)
XX
DE Human HER3 receptor extracellular domain (HF310) mutant protein.
XX
KW Therapeutic; cancer; cytostatic; pancreas tumor; stomach tumor;
KW head & neck tumor; uterine cervix tumor; lung tumor; colorectal tumor;
KW endometroid carcinoma; prostate tumor; esophagus tumor; ovary tumor;

KW uterus tumor; glioma; bladder tumor; renal tumor; breast tumor;
KW hyperproliferation; ocular disease; ophthalmological;
KW diabetic retinopathy; antidiabetic; psoriasis; antipsoriatic; restenosis;
KW vasotropic; stenosis; atherosclerosis; antiarteriosclerotic;
KW chronic obstructive airway disease; respiratory-gen.; inflammation;
KW antiinflammatory; angiogenesis disorder; antiangiogenic; gene therapy;
KW HER3; receptor; ErbB3; mutein.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Misc-difference 541
FT /note= "Wild type Gly replaced with Glu"
XX
PN WO2007146959-A2.
XX
PD 21-DEC-2007.
XX
PF 12-JUN-2007; 2007WO-US071041.
XX
PR 12-JUN-2006; 2006US-0813260P.
PR 29-SEP-2006; 2006US-0848542P.
PR 05-JAN-2007; 2007US-0878941P.
XX
PA (RECE-) RECEPTOR BIOLOGIX INC.
XX
PI Shepard HM, Jin P, Burton LE, Beryt M;
XX
DR WPI; 2008-B51284/10.
XX
PT New multimer comprising extracellular domain ECD from HER1 receptor,
PT useful for treating cancer, inflammatory disease, angiogenic disease or
PT hyperproliferative disease.
XX
PS Disclosure; Page; 320pp; English.
XX
CC The present invention provides pan-cell surface receptor specific
CC therapeutics including and pan-HER (also referred to as ErbB or EGFR)
CC specific therapeutics that interact with at least two different HER
CC receptor ligands and/or dimerize with or interact with two or more HER
CC cell surface receptors. The invention is useful for treating cancer such
CC as pancreatic, gastric, head and neck, cervical, lung, colorectal,
CC endometrial, prostate, esophageal, ovarian, uterine, glioma, bladder,
CC renal and breast cancer, proliferative diseases such as proliferation
CC and/or migration of smooth muscle cells, disease of the anterior eye,
CC diabetic retinopathy, psoriasis, restenosis, ophthalmic disorders,
CC stenosis, atherosclerosis, hypertension from thickening of blood vessels,
CC bladder diseases and obstructive airway diseases, inflammatory disease

CC and angiogenic disease. The invention is also useful in gene therapy. The
CC present sequence is human HER3 receptor (ErbB3) extracellular domain
CC mutant protein. Note: This sequence is not shown in the specification,
CC but is derived from human HER3 receptor ECD protein shown as SEQ ID NO:
CC 26 in sequence listing of the specification.
XX
SQ Sequence 621 AA;

Query Match 100.0%; Score 350; DB 2; Length 621;
Best Local Similarity 100.0%;
Matches 58; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 DIKHNRPRRDCVAEGKVCDPLCSSGGCWGPGPGQCLSCRNYSRGGVCVTHCNFLNGEP 58
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        464 DIKHNRPRRDCVAEGKVCDPLCSSGGCWGPGPGQCLSCRNYSRGGVCVTHCNFLNGEP 521
```

RESULT 8
AOG42228
ID AOG42228 standard; protein; 621 AA.
XX
AC AOG42228;
XX
DT 06-MAR-2008 (first entry)
XX
DE Human HER3 receptor extracellular domain protein, HF310.
XX
KW Therapeutic; cancer; cytostatic; pancreas tumor; stomach tumor;
KW head & neck tumor; uterine cervix tumor; lung tumor; colorectal tumor;
KW endometroid carcinoma; prostate tumor; esophagus tumor; ovary tumor;
KW uterus tumor; glioma; bladder tumor; renal tumor; breast tumor;
KW hyperproliferation; ocular disease; ophthalmological;
KW diabetic retinopathy; antidiabetic; psoriasis; antipsoriatic; restenosis;
KW vasotropic; stenosis; atherosclerosis; antiarteriosclerotic;
KW chronic obstructive airway disease; respiratory-gen.; inflammation;
KW antiinflammatory; angiogenesis disorder; antiangiogenic; gene therapy;
KW HER3; receptor; ErbB3.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Misc-difference 541
FT /note= "Encoded by GAG"
XX
PN WO2007146959-A2.
XX
PD 21-DEC-2007.
XX
PF 12-JUN-2007; 2007WO-US071041.

XX
PR 12-JUN-2006; 2006US-0813260P.
PR 29-SEP-2006; 2006US-0848542P.
PR 05-JAN-2007; 2007US-0878941P.
XX
PA (RECE-) RECEPTOR BIOLOGIX INC.
XX
PI Shepard HM, Jin P, Burton LE, Beryt M;
XX
DR WPI; 2008-B51284/10.
DR N-PSDB; AOG42227.
XX
PT New multimer comprising extracellular domain ECD from HER1 receptor,
PT useful for treating cancer, inflammatory disease, angiogenic disease or
PT hyperproliferative disease.
XX
PS Claim 95; SEQ ID NO 26; 320pp; English.
XX
CC The present invention provides pan-cell surface receptor specific
CC therapeutics including and pan-HER (also referred to as ErbB or EGFR)
CC specific therapeutics that interact with at least two different HER
CC receptor ligands and/or dimerize with or interact with two or more HER
CC cell surface receptors. The invention is useful for treating cancer such
CC as pancreatic, gastric, head and neck, cervical, lung, colorectal,
CC endometrial, prostate, esophageal, ovarian, uterine, glioma, bladder,
CC renal and breast cancer, proliferative diseases such as proliferation
CC and/or migration of smooth muscle cells, disease of the anterior eye,
CC diabetic retinopathy, psoriasis, restenosis, ophthalmic disorders,
CC stenosis, atherosclerosis, hypertension from thickening of blood vessels,
CC bladder diseases and obstructive airway diseases, inflammatory disease
CC and angiogenic disease. The invention is also useful in gene therapy. The
CC present sequence is human HER3 receptor (ErbB3) extracellular domain
CC protein.
XX
SQ Sequence 621 AA;

Query Match 100.0%; Score 350; DB 2; Length 621;
Best Local Similarity 100.0%;
Matches 58; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 DIKHNRPRRDCVAEGKVCDPLCSSGGCWGPGPGQCLSCRNYSRGGVCVTHCNFLNGEP 58
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        464 DIKHNRPRRDCVAEGKVCDPLCSSGGCWGPGPGQCLSCRNYSRGGVCVTHCNFLNGEP 521
```

RESULT 9
AEH24397
ID AEH24397 standard; protein; 624 AA.
XX

AC   AEH24397;
XX
DT   29-JUN-2006 (first entry)
XX
DE   HUMEGFRBB3_PEA_1_P15 polypeptide.
XX
KW   diagnostic; prognosis; genetic marker; screening; cancer; cytostatic;
KW   neoplasm; HUMEGFRBB3_PEA_1_P15; protein-tyrosine kinase erbB-3 precursor;
KW   ERBB3.
XX
OS   Homo sapiens.
XX
PN   WO2006043271-A1.
XX
PD   27-APR-2006.
XX
PF   16-OCT-2005; 2005WO-IL001096.
XX
PR   22-OCT-2004; 2004US-0621004P.
PR   18-NOV-2004; 2004US-0628529P.
XX
PA   (COMP-) COMPUGEN LTD.
XX
PI   Novik A, Pollock S, Levine Z, Dahary D, Sorek R, Sella-Tavor O;
PI   Cohen-Dayag A, Sameach-Greenwald S, Walach S;
XX
DR   WPI; 2006-331789/34.
DR   N-PSDB; AEH24320.
XX
PT   New isolated polynucleotide and polypeptide markers, useful as diagnostic
PT   markers for diagnosing diseases, predicting response to treatment,
PT   monitoring treatment, or determining prognosis of a marker-detectable
PT   disease.
XX
PS   Example 5; SEQ ID NO 137; 421pp; English.
XX
CC   The invention describes an isolated polynucleotide comprising
CC   HUMA1ACM_PEA 2 _T21, HUMA1ACM_PEA 2 _T27, or HUMA1ACM_PEA 2 _T7
CC   comprising 1320, 1239, or 2713 bp (SEQ ID NO. 1, 2, or 3). Also described
CC   are: an isolated polypeptide selected from HUMA1ACM_PEA 2 _P36 (SEQ ID
CC   NO. 51), HUMA1ACM_PEA 2 _P49 (SEQ ID NO. 52), or HUMA1ACM_PEA 2 _P59 (SEQ
CC   ID NO. 53); an isolated polypeptide encoding for a head of: (a)
CC   HUMA1ACM_PEA 2 _P36 comprising a polypeptide 70% homologous to SEQ ID NO.
CC   180 or 182 of HUMA1ACM_PEA 2 _P36; (b) HUMA1ACM_PEA 2 _P49 comprising a
CC   polypeptide 70% homologous to SEQ ID NO. 182 of HUMA1ACM_PEA 2 _P49; or
CC   (c) HUMA1ACM_PEA 2 _P59 comprising a polypeptide 70% homologous to SEQ ID
CC   NO. 182 of HUMA1ACM_PEA 2 _P59; an isolated polypeptide encoding for a
CC   tail of: (a) HUMA1ACM_PEA 2 _P36 comprising a polypeptide 70% homologous
CC   to SEQ ID NO. 181 in HUMA1ACM_PEA 2 _P36; (b) HUMA1ACM_PEA 2 _P49

CC comprising a polypeptide 70% homologous to SEQ ID NO. 183 in HUMA1ACM_PEA
CC 2 _P49; or (c) HUMA1ACM_PEA 2 _P59 comprising a polypeptide 70%
CC homologous to SEQ ID NO. 185 or 208 in HUMA1ACM_PEA 2 _P59; a primer pair
CC comprising a pair of isolated oligonucleotides capable of amplifying the
CC amplicon; an antibody capable of specifically binding to an epitope of
CC the amino acid sequence; a kit for detecting a marker-detectable disease
CC comprising a kit detecting specific expression of a splice variant; a
CC biomarker capable of detecting marker-detectable disease comprising the
CC nucleic acid sequences or amino acid sequence, or its fragments. The
CC polynucleotides and polypeptides are useful as diagnostic markers for
CC diagnosing and screening for diseases diseases e.g., cancer, selecting a
CC therapy for a marker-detectable disease and determining prognosis of a
CC marker-detectable disease, as well as for predicting response to
CC treatment and monitoring treatment. This sequence represents a
CC HUMEGFRBB3_PEA_1_P15 polypeptide, a transcript from the HUMEGFRBB3
CC cluster and variant of protein-tyrosine kinase erbB-3 precursor useful as
CC a diagnostic marker.
XX
SQ Sequence 624 AA;

Query Match 100.0%; Score 350; DB 2; Length 624;
Best Local Similarity 100.0%;
Matches 58; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 DIKHNRPRRDCVAEGKVCDPLCSSGGCWGPGPGQCLSCRNYSRGGVCVTHCNFLNGEP 58
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        483 DIKHNRPRRDCVAEGKVCDPLCSSGGCWGPGPGQCLSCRNYSRGGVCVTHCNFLNGEP 540
```

RESULT 10
AEH24406
ID AEH24406 standard; protein; 624 AA.
XX
AC AEH24406;
XX
DT 29-JUN-2006 (first entry)
XX
DE HUMEGFRBB3_PEA_1_P55 polypeptide.
XX
KW diagnostic; prognosis; genetic marker; screening; cancer; cytostatic;
KW neoplasm; HUMEGFRBB3_PEA_1_P55; protein-tyrosine kinase erbB-3 precursor;
KW ERBB3.
XX
OS Homo sapiens.
XX
PN WO2006043271-A1.
XX
PD 27-APR-2006.
XX

PF 16-OCT-2005; 2005WO-IL001096.
XX
PR 22-OCT-2004; 2004US-0621004P.
PR 18-NOV-2004; 2004US-0628529P.
XX
PA (COMP-) COMPUGEN LTD.
XX
PI Novik A, Pollock S, Levine Z, Dahary D, Sorek R, Sella-Tavor O;
PI Cohen-Dayag A, Sameach-Greenwald S, Walach S;
XX
DR WPI; 2006-331789/34.
DR N-PSDB; AEH24323.
XX
PT New isolated polynucleotide and polypeptide markers, useful as diagnostic
PT markers for diagnosing diseases, predicting response to treatment,
PT monitoring treatment, or determining prognosis of a marker-detectable
PT disease.
XX
PS Example 5; SEQ ID NO 146; 421pp; English.
XX
CC The invention describes an isolated polynucleotide comprising
CC HUMA1ACM_PEA 2 _T21, HUMA1ACM_PEA 2 _T27, or HUMA1ACM_PEA 2 _T7
CC comprising 1320, 1239, or 2713 bp (SEQ ID NO. 1, 2, or 3). Also described
CC are: an isolated polypeptide selected from HUMA1ACM_PEA 2 _P36 (SEQ ID
CC NO. 51), HUMA1ACM_PEA 2 _P49 (SEQ ID NO. 52), or HUMA1ACM_PEA 2 _P59 (SEQ
CC ID NO. 53); an isolated polypeptide encoding for a head of: (a)
CC HUMA1ACM_PEA 2 _P36 comprising a polypeptide 70% homologous to SEQ ID NO.
CC 180 or 182 of HUMA1ACM_PEA 2 _P36; (b) HUMA1ACM_PEA 2 _P49 comprising a
CC polypeptide 70% homologous to SEQ ID NO. 182 of HUMA1ACM_PEA 2 _P49; or
CC (c) HUMA1ACM_PEA 2 _P59 comprising a polypeptide 70% homologous to SEQ ID
CC NO. 182 of HUMA1ACM_PEA 2 _P59; an isolated polypeptide encoding for a
CC tail of: (a) HUMA1ACM_PEA 2 _P36 comprising a polypeptide 70% homologous
CC to SEQ ID NO. 181 in HUMA1ACM_PEA 2 _P36; (b) HUMA1ACM_PEA 2 _P49
CC comprising a polypeptide 70% homologous to SEQ ID NO. 183 in HUMA1ACM_PEA
CC 2 _P49; or (c) HUMA1ACM_PEA 2 _P59 comprising a polypeptide 70%
CC homologous to SEQ ID NO. 185 or 208 in HUMA1ACM_PEA 2 _P59; a primer pair
CC comprising a pair of isolated oligonucleotides capable of amplifying the
CC amplicon; an antibody capable of specifically binding to an epitope of
CC the amino acid sequence; a kit for detecting a marker-detectable disease
CC comprising a kit detecting specific expression of a splice variant; a
CC biomarker capable of detecting marker-detectable disease comprising the
CC nucleic acid sequences or amino acid sequence, or its fragments. The
CC polynucleotides and polypeptides are useful as diagnostic markers for
CC diagnosing and screening for diseases diseases e.g., cancer, selecting a
CC therapy for a marker-detectable disease and determining prognosis of a
CC marker-detectable disease, as well as for predicting response to
CC treatment and monitoring treatment. This sequence represents a
CC HUMEGFRBB3_PEA_1_P55 polypeptide, a transcript from the HUMEGFRBB3
CC cluster and variant of protein-tyrosine kinase erbB-3 precursor useful as

```
CC   a diagnostic marker.
XX
SQ   Sequence 624 AA;

  Query Match             100.0%;  Score 350;  DB 2;  Length 624;
  Best Local Similarity   100.0%;
  Matches   58;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 DIKHNRPRRDCVAEGKVCDPLCSSGGCWGPGPGQCLSCRNYSRGGVCVTHCNFLNGEP 58
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        483 DIKHNRPRRDCVAEGKVCDPLCSSGGCWGPGPGQCLSCRNYSRGGVCVTHCNFLNGEP 540


RESULT 11
ATT39332
ID   ATT39332 standard; protein; 625 AA.
XX
AC   ATT39332;
XX
DT   08-JAN-2009  (first entry)
XX
DE   Human ERBB3-intein fusion protein SEQ ID 193.
XX
KW   protein production; chimeric protein; nanotechnology;
KW   antibody engineering; antibody production; gene regulation;
KW   antibody therapy; therapeutic; cancer; metastasis; non-hodgkin lymphoma;
KW   asthma; rheumatoid arthritis; psoriatic arthritis;
KW   ankylosing spondylitis; Crohns disease; colorectal tumor;
KW   autoimmune disease; antiallergic; antiarthritic; antiasthmatic;
KW   antiinflammatory; cytostatic; gastrointestinal-gen.; hematological-gen.;
KW   immunomodulator; immunosuppressive; musculoskeletal-gen.;
KW   respiratory-gen.; Erbb3 tyrosine kinase receptor; intein; fusion protein.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   US2008254512-A1.
XX
PD   16-OCT-2008.
XX
PF   31-OCT-2007; 2007US-00982085.
XX
PR   02-NOV-2006; 2006US-0856864P.
XX
PA   (CAPO/) CAPON D J.
XX
PI   Capon DJ;
XX
DR   WPI; 2008-O15609/82.
```

XX
PT New compound that comprises an independently folding protein domain fused
PT to a second independently folding protein domain by non-peptide bond for
PT treating e.g. cancer, metastatic disease, asthma, rheumatoid arthritis
PT and autoimmune disease.
XX
PS Example 9; SEQ ID NO 193; 363pp; English.
XX
CC The present invention relates to a novel compound comprising an
CC independently folding protein domain fused to a second independently
CC folding protein domain by a non-peptide bond around which dihedral
CC rotation may occur. The invention, in particular, relates to hybrid
CC immunoglobulins containing moving parts, related compositions, methods of
CC use, methods of production of such hybrid immunoglobulins; and to
CC analogous genetic devices, preferably nanodevices. The protein-like
CC compounds (preferably immunoglobulins) and their dimers and multimers are
CC useful for affecting the activity of a target, e.g. epidermal growth
CC factor (EGF) receptor, human epidermal growth factor receptor 2 (HER2),
CC vascular endothelial growth factor (VEGF) receptor (e.g. VEGFR1, VEGFR6,
CC and VEGFR3), CD20 antigen, CD11a leukocyte receptor, IgE immunoglobulin,
CC glycoprotein IIa receptor, glycoprotein IIIa receptor, tumor necrosis
CC factor (TNF) alpha (e.g. TNFRSF1a, and TNFRSF1b), or TNF receptor, gap
CC protein 120 (gp120), human Erb1 (proto-oncogene), Erb2, Erb6, Erb3 and
CC Erb4; useful for treating e.g. cancer, metastatic disease, B-cell non-
CC Hodgkin's lymphoma, asthma, a subject having a skin test positive for
CC perennial aerocollagen, rheumatoid arthritis, psoriatic arthritis,
CC ankylosing spondylitis, Crohn's disease, fustulizing disease, metastatic
CC colorectal carcinoma, as an adjunct to percutaneous coronary
CC intervention, and autoimmune diseases. The present sequence represents a
CC fusion protein comprising the human Erbb3 tyrosine kinase receptor fused
CC with the human intein polypeptide which was useful during the method of
CC the invention for the production of hybrid immunoglobulins.
XX
SQ Sequence 625 AA;

Query Match 100.0%; Score 350; DB 2; Length 625;
Best Local Similarity 100.0%;
Matches 58; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 DIKHNRPRRDCVAEGKVCDPLCSSGGCWGPGPGQCLSCRNYSRGGVCVTHCNFLNGEP 58
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        464 DIKHNRPRRDCVAEGKVCDPLCSSGGCWGPGPGQCLSCRNYSRGGVCVTHCNFLNGEP 521
```

RESULT 12
ATT39333
ID ATT39333 standard; protein; 626 AA.
XX
AC ATT39333;

XX
DT 08-JAN-2009 (first entry)
XX
DE Human ERBB3-intein fusion protein SEQ ID 194.
XX
KW protein production; chimeric protein; nanotechnology;
KW antibody engineering; antibody production; gene regulation;
KW antibody therapy; therapeutic; cancer; metastasis; non-hodgkin lymphoma;
KW asthma; rheumatoid arthritis; psoriatic arthritis;
KW ankylosing spondylitis; Crohns disease; colorectal tumor;
KW autoimmune disease; antiallergic; antiarthritic; antiasthmatic;
KW antiinflammatory; cytostatic; gastrointestinal-gen.; hematological-gen.;
KW immunomodulator; immunosuppressive; musculoskeletal-gen.;
KW respiratory-gen.; Erbb3 tyrosine kinase receptor; intein; fusion protein.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN US2008254512-A1.
XX
PD 16-OCT-2008.
XX
PF 31-OCT-2007; 2007US-00982085.
XX
PR 02-NOV-2006; 2006US-0856864P.
XX
PA (CAPO/) CAPON D J.
XX
PI Capon DJ;
XX
DR WPI; 2008-O15609/82.
XX
PT New compound that comprises an independently folding protein domain fused
PT to a second independently folding protein domain by non-peptide bond for
PT treating e.g. cancer, metastatic disease, asthma, rheumatoid arthritis
PT and autoimmune disease.
XX
PS Example 9; SEQ ID NO 194; 363pp; English.
XX
CC The present invention relates to a novel compound comprising an
CC independently folding protein domain fused to a second independently
CC folding protein domain by a non-peptide bond around which dihedral
CC rotation may occur. The invention, in particular, relates to hybrid
CC immunoglobulins containing moving parts, related compositions, methods of
CC use, methods of production of such hybrid immunoglobulins; and to
CC analogous genetic devices, preferably nanodevices. The protein-like
CC compounds (preferably immunoglobulins) and their dimers and multimers are
CC useful for affecting the activity of a target, e.g. epidermal growth
CC factor (EGF) receptor, human epidermal growth factor receptor 2 (HER2),

```
CC   vascular endothelial growth factor (VEGF) receptor (e.g. VEGFR1, VEGFR6,
CC   and VEGFR3), CD20 antigen, CD11a leukocyte receptor, IgE immunoglobulin,
CC   glycoprotein IIa receptor, glycoprotein IIIa receptor, tumor necrosis
CC   factor (TNF) alpha (e.g. TNFRSF1a, and TNFRSF1b), or TNF receptor, gap
CC   protein 120 (gp120), human Erb1 (proto-oncogene), Erb2, Erb6, Erb3 and
CC   Erb4; useful for treating e.g. cancer, metastatic disease, B-cell non-
CC   Hodgkin's lymphoma, asthma, a subject having a skin test positive for
CC   perennial aerocollagen, rheumatoid arthritis, psoriatic arthritis,
CC   ankylosing spondylitis, Crohn's disease, fustulizing disease, metastatic
CC   colorectal carcinoma, as an adjunct to percutaneous coronary
CC   intervention, and autoimmune diseases. The present sequence represents a
CC   fusion protein comprising the human Erbb3 tyrosine kinase receptor fused
CC   with the human intein polypeptide which was useful during the method of
CC   the invention for the production of hybrid immunoglobulins.
XX
SQ   Sequence 626 AA;

  Query Match             100.0%;  Score 350;  DB 2;  Length 626;
  Best Local Similarity   100.0%;
  Matches   58;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 DIKHNRPRRDCVAEGKVCDPLCSSGGCWGPGPGQCLSCRNYSRGGVCVTHCNFLNGEP 58
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        464 DIKHNRPRRDCVAEGKVCDPLCSSGGCWGPGPGQCLSCRNYSRGGVCVTHCNFLNGEP 521


RESULT 13
ADE36713
ID   ADE36713 standard; protein; 640 AA.
XX
AC   ADE36713;
XX
DT   29-JAN-2004  (first entry)
XX
DE   Human ErbB-3 partial amino acid sequence SEQ ID NO:2.
XX
KW   neoplasm; ErbB-3; immune response; cytostatic; gene therapy; cancer;
KW   human.
XX
OS   Homo sapiens.
XX
PN   WO2003080835-A1.
XX
PD   02-OCT-2003.
XX
PF   26-MAR-2003; 2003WO-CN000217.
XX
PR   26-MAR-2002; 2002CN-00116259.
XX
```

PA (ZENS-) ZENSUN SHANGHAI SCI TECH LTD.
XX
PI Zhou M;
XX
DR WPI; 2003-876924/81.
XX
PT Use of an ErbB-3 protein, a nucleic acid encoding an ErbB-3 protein or
PT their fragments, for treating, preventing or delaying neoplasms (e.g.
PT urethra, uterus, vagina or vulva neoplasm) or cancers (e.g. breast, ovary
PT or colon cancer).
XX
PS Claim 22; SEQ ID NO 2; 68pp; English.
XX
CC The present invention describes a method for treating, preventing or
CC delaying neoplasm in a mammal. The method comprises administering an ErbB
CC -3 protein, a nucleic acid encoding an ErbB-3 protein, or their
CC functional fragments, where an immune response is generated against the
CC neoplasm. ErbB-3 has cytostatic activity, and can be used in gene
CC therapy. The method is useful for treating, preventing or delaying
CC neoplasms (e.g. adrenal gland, anus, auditory nerve, bile ducts, bladder,
CC bone, brain, breast, buccal, central nervous system, cervix, colon, ear,
CC endometrium, oesophagus, eye, eyelids, fallopian tube, gastrointestinal
CC tract, head and neck, heart, kidney, larynx, liver, lung, mandible,
CC mandibular condyle, maxilla, mouth, nasopharynx, nose, oral cavity,
CC ovary, pancreas, parotid gland, penis, pinna, pituitary, prostate gland,
CC rectum, retina, salivary glands, skin, small intestine, spinal cord,
CC stomach, testes, thyroid, tonsil, urethra, uterus, vagina,
CC vestibulocochlear nerve, or vulva neoplasm), or cancers (breast, ovary,
CC stomach, prostate, colon and lung cancer). The present sequence
CC represents a human ErbB-3 amino acid sequence, which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 640 AA;

Query Match 100.0%; Score 350; DB 1; Length 640;
Best Local Similarity 100.0%;
Matches 58; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 DIKHNRPRRDCVAEGKVCDPLCSSGGCWGPGPGQCLSCRNYSRGGVCVTHCNFLNGEP 58
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        483 DIKHNRPRRDCVAEGKVCDPLCSSGGCWGPGPGQCLSCRNYSRGGVCVTHCNFLNGEP 540
```

RESULT 14
ADW39268
ID ADW39268 standard; protein; 640 AA.
XX
AC ADW39268;
XX

DT 24-MAR-2005 (first entry)
XX
DE Human Erb-3 polypeptide SEQ ID NO 2.
XX
KW therapy; tumor; cytostatic; neoplasm; ErbB-3.
XX
OS Homo sapiens.
XX
PN CN1444992-A.
XX
PD 01-OCT-2003.
XX
PF 26-MAR-2002; 2002CN-00116259.
XX
PR 18-MAR-2002; 2002CN-00107357.
XX
PA (ZESH-) ZESHENG SCI & TECHNOLOGY DEV CO LTD SHAN.
XX
PI Zhou M;
XX
DR WPI; 2004-091783/10.
XX
PT Method and combination for treating tumors based on ERBB-3.
XX
PS Claim 5; SEQ ID NO 2; 45pp; Chinese.
XX
CC The invention describes a composition and method for preventing and
CC treating a tumor of the mammalian or human body. The method involves
CC using the ErbB-3 protein, nucleic acid for encoding the protein, or their
CC functional fragment e.g. the extracellular domain. This is the amino acid
CC sequence of a human Erb-3 polypeptide.
XX
SQ Sequence 640 AA;

Query Match 100.0%; Score 350; DB 1; Length 640;
Best Local Similarity 100.0%;
Matches 58; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 DIKHNRPRRDCVAEGKVCDPLCSSGGCWGPGPGQCLSCRNYSRGGVCVTHCNFLNGEP 58
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        483 DIKHNRPRRDCVAEGKVCDPLCSSGGCWGPGPGQCLSCRNYSRGGVCVTHCNFLNGEP 540
```

RESULT 15
AEH24399
ID AEH24399 standard; protein; 699 AA.
XX
AC AEH24399;
XX

DT 29-JUN-2006 (first entry)
XX
DE HUMEGFRBB3_PEA_1_P31 polypeptide.
XX
KW diagnostic; prognosis; genetic marker; screening; cancer; cytostatic;
KW neoplasm; HUMEGFRBB3_PEA_1_P31; protein-tyrosine kinase erbB-3 precursor;
KW ERBB3.
XX
OS Homo sapiens.
XX
PN WO2006043271-A1.
XX
PD 27-APR-2006.
XX
PF 16-OCT-2005; 2005WO-IL001096.
XX
PR 22-OCT-2004; 2004US-0621004P.
PR 18-NOV-2004; 2004US-0628529P.
XX
PA (COMP-) COMPUGEN LTD.
XX
PI Novik A, Pollock S, Levine Z, Dahary D, Sorek R, Sella-Tavor O;
PI Cohen-Dayag A, Sameach-Greenwald S, Walach S;
XX
DR WPI; 2006-331789/34.
DR N-PSDB; AEH24326.
XX
PT New isolated polynucleotide and polypeptide markers, useful as diagnostic
PT markers for diagnosing diseases, predicting response to treatment,
PT monitoring treatment, or determining prognosis of a marker-detectable
PT disease.
XX
PS Example 5; SEQ ID NO 139; 421pp; English.
XX
CC The invention describes an isolated polynucleotide comprising
CC HUMA1ACM_PEA 2 _T21, HUMA1ACM_PEA 2 _T27, or HUMA1ACM_PEA 2 _T7
CC comprising 1320, 1239, or 2713 bp (SEQ ID NO. 1, 2, or 3). Also described
CC are: an isolated polypeptide selected from HUMA1ACM_PEA 2 _P36 (SEQ ID
CC NO. 51), HUMA1ACM_PEA 2 _P49 (SEQ ID NO. 52), or HUMA1ACM_PEA 2 _P59 (SEQ
CC ID NO. 53); an isolated polypeptide encoding for a head of: (a)
CC HUMA1ACM_PEA 2 _P36 comprising a polypeptide 70% homologous to SEQ ID NO.
CC 180 or 182 of HUMA1ACM_PEA 2 _P36; (b) HUMA1ACM_PEA 2 _P49 comprising a
CC polypeptide 70% homologous to SEQ ID NO. 182 of HUMA1ACM_PEA 2 _P49; or
CC (c) HUMA1ACM_PEA 2 _P59 comprising a polypeptide 70% homologous to SEQ ID
CC NO. 182 of HUMA1ACM_PEA 2 _P59; an isolated polypeptide encoding for a
CC tail of: (a) HUMA1ACM_PEA 2 _P36 comprising a polypeptide 70% homologous
CC to SEQ ID NO. 181 in HUMA1ACM_PEA 2 _P36; (b) HUMA1ACM_PEA 2 _P49
CC comprising a polypeptide 70% homologous to SEQ ID NO. 183 in HUMA1ACM_PEA
CC 2 _P49; or (c) HUMA1ACM_PEA 2 _P59 comprising a polypeptide 70%

CC homologous to SEQ ID NO. 185 or 208 in HUMA1ACM_PEA 2 _P59; a primer pair
CC comprising a pair of isolated oligonucleotides capable of amplifying the
CC amplicon; an antibody capable of specifically binding to an epitope of
CC the amino acid sequence; a kit for detecting a marker-detectable disease
CC comprising a kit detecting specific expression of a splice variant; a
CC biomarker capable of detecting marker-detectable disease comprising the
CC nucleic acid sequences or amino acid sequence, or its fragments. The
CC polynucleotides and polypeptides are useful as diagnostic markers for
CC diagnosing and screening for diseases diseases e.g., cancer, selecting a
CC therapy for a marker-detectable disease and determining prognosis of a
CC marker-detectable disease, as well as for predicting response to
CC treatment and monitoring treatment. This sequence represents a
CC HUMEGFRBB3_PEA_1_P31 polypeptide, a transcript from the HUMEGFRBB3
CC cluster and variant of protein-tyrosine kinase erbB-3 precursor useful as
CC a diagnostic marker.
XX
SQ Sequence 699 AA;

Query Match 100.0%; Score 350; DB 2; Length 699;
Best Local Similarity 100.0%;
Matches 58; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 DIKHNRPRRDCVAEGKVCDPLCSSGGCWGPGPGQCLSCRNYSRGGVCVTHCNFLNGEP 58
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        483 DIKHNRPRRDCVAEGKVCDPLCSSGGCWGPGPGQCLSCRNYSRGGVCVTHCNFLNGEP 540
```

Search completed: November 23, 2009, 11:14:49
Job time : 58 secs

SCORE 3.0